Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | AdAPT-001 |
| Trade Name | |
| Synonyms | AdAPT 001|AdAPT001 |
| Drug Descriptions |
AdAPT-001 is an oncolytic adenovirus engineered to express a fusion protein composed of soluble TGFBR2 and the Fc region of IgG1, which binds to and sequesters TGFbeta, potentially inhibiting downstream signaling and tumor growth (PMID: 35950603). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C179574 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| AdAPT-001 | AdAPT-001 | 0 | 1 |
| AdAPT-001 + unspecified immune checkpoint inhibitor | AdAPT-001 unspecified immune checkpoint inhibitor | 0 | 1 |